Influence of socioeconomic status on functional recovery after ARDS caused by SARS-CoV-2: a multicentre, observational study.
COVID-19
intensive & critical care
respiratory infections
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
22 04 2022
22 04 2022
Historique:
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Prognosis of patients with COVID-19 depends on the severity of the pulmonary affection. The most severe cases may progress to acute respiratory distress syndrome (ARDS), which is associated with a risk of long-term repercussions on respiratory function and neuromuscular outcomes. The functional repercussions of severe forms of COVID-19 may have a major impact on quality of life, and impair the ability to return to work or exercise. Social inequalities in healthcare may influence prognosis, with socially vulnerable individuals more likely to develop severe forms of disease. We describe here the protocol for a prospective, multicentre study that aims to investigate the influence of social vulnerability on functional recovery in patients who were hospitalised in intensive care for ARDS caused by COVID-19. This study will also include an embedded qualitative study that aims to describe facilitators and barriers to compliance with rehabilitation, describe patients' health practices and identify social representations of health, disease and care. The "Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status" (RECOVIDS) study is a mixed-methods, observational, multicentre cohort study performed during the routine follow-up of post-intensive care unit (ICU) functional recovery after ARDS. All patients admitted to a participating ICU for PCR-proven SARS-CoV-2 infection and who underwent chest CT scan at the initial phase AND who received respiratory support (mechanical or not) or high-flow nasal oxygen, AND had ARDS diagnosed by the Berlin criteria will be eligible. The primary outcome is the presence of lung sequelae at 6 months after ICU discharge, defined either by alterations on pulmonary function tests, oxygen desaturation during a standardised 6 min walk test or fibrosis-like pulmonary findings on chest CT. Patients will be considered to be socially disadvantaged if they have an "Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examen de Santé" (EPICES) score ≥30.17 at inclusion. The study protocol and the informed consent form were approved by an independent ethics committee (Comité de Protection des Personnes Sud Méditerranée II) on 10 July 2020 (2020-A02014-35). All patients will provide informed consent before participation. Findings will be published in peer-reviewed journals and presented at national and international congresses. NCT04556513.
Identifiants
pubmed: 35459672
pii: bmjopen-2021-057368
doi: 10.1136/bmjopen-2021-057368
pmc: PMC9035836
doi:
Substances chimiques
Oxygen
S88TT14065
Banques de données
ClinicalTrials.gov
['NCT04556513']
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e057368Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur J Public Health. 2015 Aug;25(4):604-9
pubmed: 25624273
J Epidemiol Community Health. 2020 Aug;74(8):620-623
pubmed: 32385126
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Ann Intensive Care. 2020 Feb 11;10(1):20
pubmed: 32048075
Chest. 2013 Jul;144(1):24-31
pubmed: 23699588
Eur J Emerg Med. 2020 Aug;27(4):274-278
pubmed: 32516161
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
JAMA. 2020 Jun 2;323(21):2191-2192
pubmed: 32338732
Eur Respir J. 2014 Dec;44(6):1428-46
pubmed: 25359355
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Public Health. 2012 Aug;102(8):e51-8
pubmed: 22698024
Eur J Neurol. 2021 Mar;28(3):800-808
pubmed: 33098727
Int J Chron Obstruct Pulmon Dis. 2009;4:9-18
pubmed: 19436682
Occup Med (Lond). 2017 Aug 1;67(6):496-497
pubmed: 28898975
J Epidemiol Community Health. 2012 Nov;66(11):982-9
pubmed: 22544918
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
JAMA. 2020 Jun 2;323(21):2192-2195
pubmed: 32347898
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
Qual Health Res. 2017 Mar;27(4):591-608
pubmed: 27670770
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Diabetes Metab. 2012 Feb;38(1):82-5
pubmed: 22172401
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
BMJ Open. 2020 Mar 18;10(3):e033751
pubmed: 32193263
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
N Engl J Med. 2003 Feb 20;348(8):683-93
pubmed: 12594312
PLoS One. 2020 Apr 2;15(4):e0230661
pubmed: 32240217
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151